Johnson & Johnson (JNJ) Q3 FY25 earnings call

Johnson & Johnson delivered a strong third quarter, demonstrating accelerated growth across its Innovative Medicine and MedTech segments, even as it navigated the STELARA loss of exclusivity. The company announced the planned separation of its Orthopaedics business, DePuy Synthes, to sharpen focus on high-growth areas like oncology, immunology, neuroscience, cardiovascular, surgery, and vision. This strategic move aims to optimize portfolio performance and drive long-term value creation for both entities.